No Data
No Data
Intellia Therapeutics Analyst Ratings
Gene Therapy Developers Rise on Comments From FDA's Makary
$NTLA Stock Is up 10% Today. Here's What We See in Our Data.
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Wolfe Research Upgrades Intellia Therapeutics(NTLA.US) to Buy Rating, Announces Target Price $21
Intellia Therapeutics Upgraded to Outperform From Peer Perform at Wolfe Research